attendees.bizzabo.com Open in urlscan Pro
2606:4700::6812:1634  Public Scan

Submitted URL: https://u29002428.ct.sendgrid.net/ls/click?upn=fQFYBBQ6qHesxPRxeHpraPj-2FZ-2BDnkZNTLf6Nmzj3XIVNiNmfhawMBSxuJlPAJY3Gikaym4dJZtDIeIi...
Effective URL: https://attendees.bizzabo.com/536217?source=magic_link
Submission: On December 06 via api from DE — Scanned from DE

Form analysis 0 forms found in the DOM

Text Content

You need to enable JavaScript to run this app.
 * Agenda
 * More Info

More

09.13
09.14

Favorites

9:00AM Your Local Time (GMT+1)
3hr 40min.
Watch Recording

Day 2 - first session
 * 09:00–09:05
   Opening remarks from QIAGEN
 * 09:05–09:40
   Presentation
   Comprehensive evaluation for risk classification and treatment selection for
   Ph- ALL
   Speaker: Dr. Nicola Gökbuget, University Hospital Frankfurt, Germany
 * 09:40–10:15
   Presentation
   MRD as a tool to evaluate treatment response and predict relapse in Ph+ ALL
   Speaker: Dr. Rathana Kim, Department of Molecular Hematology, Hematology
   Laboratory, Hôpital Saint-Louis, Paris, France
 * 10:15–10:50
   Presentation
   Importance of testing in multiple myeloma
   Speaker: Dr. Claudio Cerchione, Istituto Romagnolo per lo Studio dei Tumori
   "Dino Amadori" – IRST IRCCS, Meldola, Italy
 * 10:50–11:25
   Presentation
   A conversation with Prof. Albrecht Stenzinger: IVDR strategy
   Speaker: Prof. Albrecht Stenzinger, Institute of Pathology, University
   Hospital Heidelberg, Germany
 * 11:25–12:40
   Lunch and networking

Read more


 * 09:00–09:05
   Opening remarks from QIAGEN
 * 09:05–09:40
   Presentation
   Comprehensive evaluation for risk classification and treatment selection for
   Ph- ALL
   Speaker: Dr. Nicola Gökbuget, University Hospital Frankfurt, Germany
 * 09:40–10:15
   Presentation
   MRD as a tool to evaluate treatment response and predict relapse in Ph+ ALL
   Speaker: Dr. Rathana Kim, Department of Molecular Hematology, Hematology
   Laboratory, Hôpital Saint-Louis, Paris, France
 * 10:15–10:50
   Presentation
   Importance of testing in multiple myeloma
   Speaker: Dr. Claudio Cerchione, Istituto Romagnolo per lo Studio dei Tumori
   "Dino Amadori" – IRST IRCCS, Meldola, Italy
 * 10:50–11:25
   Presentation
   A conversation with Prof. Albrecht Stenzinger: IVDR strategy
   Speaker: Prof. Albrecht Stenzinger, Institute of Pathology, University
   Hospital Heidelberg, Germany
 * 11:25–12:40
   Lunch and networking

Read more
12:40PM Your Local Time (GMT+1)
2hr 45min.
Watch Recording

Day 2 - second session
 * 12:40–13:15
   Presentation
   JAK2 V617F monitoring in MPN
   Speaker: Prof. Jean-Jacques Kiladjian, Clinical Investigations Center,
   Saint-Louis Hospital & the University of Paris, Paris, France
 * 13:15–13:50
   Presentation
   Using molecular testing to detect biomarker heterogeneity within MPN
   Speaker: Dr. Bruno Cassinat, Department of Cell Biology, Saint-Louis
   Hospital, Paris, France
 * 13:50–14:25
   Presentation
   Approaches to select patients for CAR T-cell therapy
   Speaker: Dr. Jae Hong Park, Memorial Sloan Kettering Cancer Center, New York,
   USA
 * 14:25–15:10
   Patient perspective
   A testimonial from a cancer survivor on CAR T-cell therapy
   Speaker: Tom Whitehead, Co-founder of the Emily Whitehead Foundation,
   Philipsburg, USA
 * 15:10–15:25
   Closing remarks from QIAGEN

Read more


 * 12:40–13:15
   Presentation
   JAK2 V617F monitoring in MPN
   Speaker: Prof. Jean-Jacques Kiladjian, Clinical Investigations Center,
   Saint-Louis Hospital & the University of Paris, Paris, France
 * 13:15–13:50
   Presentation
   Using molecular testing to detect biomarker heterogeneity within MPN
   Speaker: Dr. Bruno Cassinat, Department of Cell Biology, Saint-Louis
   Hospital, Paris, France
 * 13:50–14:25
   Presentation
   Approaches to select patients for CAR T-cell therapy
   Speaker: Dr. Jae Hong Park, Memorial Sloan Kettering Cancer Center, New York,
   USA
 * 14:25–15:10
   Patient perspective
   A testimonial from a cancer survivor on CAR T-cell therapy
   Speaker: Tom Whitehead, Co-founder of the Emily Whitehead Foundation,
   Philipsburg, USA
 * 15:10–15:25
   Closing remarks from QIAGEN

Read more

Messages